The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

about

Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.High Spy1 expression predicts poor prognosis in colorectal cancer

P2860

Q55005865-47572953-2D3E-4C9D-80F1-B4CD7B03EA8C Q55091523-0C396865-2E51-4C0D-86A2-7D96D5D2F7A3 Q58773752-F0D336C8-5DA4-4FC1-8F67-52FE9363164F

P2860

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

Item

http://www.wikidata.org/entity/Q48169849

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@en

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@nl

type

Item

label

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@en

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@nl

prefLabel

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@en

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@nl

P1476

The CDK4/6 inhibitor palbocicl ...... ncer cell death under hypoxia.

@en

P2093

David T Dicker

http://www.w3.org/2001/XMLSchema#string

Jun Zhang

http://www.w3.org/2001/XMLSchema#string

Shuai Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression.

MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.

P304

1193-1200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15384101.2017.1320005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wafik S. El-Deiry

Lanlan Zhou

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28486050

http://www.w3.org/2001/XMLSchema#string

P921

hypoxia

colorectal cancer

P932

5499912

http://www.w3.org/2001/XMLSchema#string

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

about

P2860

P2860

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932